Fig. 2

Immunoblot analysis of downstream phosphoproteins inhibited by IM, SC and DOR treatment. Ai + ii & Bi + ii K562 cells were treated with IM (0.35 µM, 0.7 µM), SC (0.5 µM, 1 µM, 2 µM) and the combination SC (1 µM or 2 µM) + DOR (2.5 µM) for 4 h or 24 h followed by analysis of down-stream targets of BCR::ABL1 signalling; p–c-Abl, p-STAT5, p-CRKL and SFKs (n = 3). SH-PTP2 and total SRC were used as loading control. Ci + ii CompuSyn analysis of treated CP-CML CD34.⁺ cells confirmed SC in combination with DOR works in a synergistic manner. C-i CompuSyn is calculating the fraction affected (Fa) of each drug on its own or combination and C-ii ranks those values with a combination index (CI). The CI for all drug combinations is below 1, which defines synergy. See also Figure S1